On July 12丨July 10, Novo Hui Health (6606.HK) expects to achieve operating income of 799-837 million yuan in the first half of 2023, an increase of 254.2%-270.8% over the previous year. It is expected to achieve gross profit of 730-754 million yuan, an increase of 294.6%-307.3% over the previous year. According to the research report of Zhongtai Securities on the 11th, the company's performance in the first half of the year exceeded expectations. According to the semi-annual performance forecast, adjusted profit forecasts are expected to accelerate sales of the three major products as cancer screening market awareness continues to rise. The company is expected to achieve operating income of 17.43, 30.00, 4.557 billion yuan (1,432, 25.82, 4.551 billion yuan before adjustment), up 128%, 72%, and 52% year-on-year. It is expected to achieve net profit of -0.14, 2.21, 778 million yuan in 2025 (0.13, 2.01, 776 million yuan before adjustment), The year-on-year increase in 2024-2025 was 255%. Consider that the company is a leading listed company for early cancer screening in China. It has large market space, a good competitive pattern, fast performance growth rate, good scarcity, and maintains a “buy” rating.
研报掘金丨中泰证券：诺辉健康中期业绩超预期，三大产品有望加速放量，维持“买入”评级
Research Report Nuggets | Zhongtai Securities: Nuohui Health's interim results have exceeded expectations, and the three major products are expected to accelerate sales and maintain the “buy” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.